DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Fareston (Toremifene Citrate) - Summary

 
 



WARNING: QT PROLONGATION

FARESTON has been shown to prolong the QTc interval in a dose- and concentration-related manner [see Clinical Pharmacolog y (12.2)] . Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided [ see Warnings and Precautions (5.1 ) ].

 

FARESTON SUMMARY

FARESTON (toremifene citrate) Tablets for oral administration each contain 88.5 mg of toremifene citrate, which is equivalent to 60 mg toremifene.

FARESTON is indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.


See all Fareston indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Fareston (Toremifene)

Oncotype DX Impacts Chemotherapy Decisions in Breast Cancer
Source: Medscape Hematology-Oncology Headlines [2015.08.28]
A large cohort study demonstrated that Oncotype DX testing was associated with less frequent chemotherapy use in high-risk patients, but more frequent use in low-risk women.
Medscape Medical News

Medical News Today: Breast cancer relapse could be predicted with new blood test
Source: Featured Health News from Medical News Today [2015.08.27]
A new study reports that a so-called ‘mutation-tracking' blood test can pick up valuable signs of cancer’s potential return, offering hope to patients with the disease.

Breast cancer relapse could be predicted with new blood test
Source: Blood / Hematology News From Medical News Today [2015.08.27]
A new study reports that a so-called ‘mutation-tracking' blood test can pick up valuable signs of cancer’s potential return, offering hope to patients with the disease.

New 'mutation-tracking' blood test could predict breast cancer relapse months in advance
Source: Blood / Hematology News From Medical News Today [2015.08.27]
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.

21-gene recurrence score and receipt of chemotherapy in patients with breast cancer
Source: Breast Cancer News From Medical News Today [2015.08.27]
Use of the 21-gene recurrence test score was associated with lower chemotherapy use in high-risk patients and greater use of chemotherapy in low-risk patients compared with not using the test among...

more news >>

Published Studies Related to Fareston (Toremifene)

Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. [2013]
high-grade prostatic intraepithelial neoplasia (HGPIN) on biopsy... CONCLUSION: Although toremifene 20 mg did not lower the PCa detection rate, men

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2013]
therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral

Toremifene decreases vertebral fractures in men younger than 80 years receiving androgen deprivation therapy for prostate cancer. [2011]
men younger than 80 years... CONCLUSIONS: Toremifene significantly decreased new vertebral fractures in men

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. [2010.10]
PURPOSE: Androgen deprivation therapy is associated with fracture risk in men with prostate cancer. We assessed the effects of toremifene, a selective estrogen receptor modulator, on fracture incidence in men receiving androgen deprivation therapy during a 2-year period... CONCLUSIONS: Toremifene significantly decreased the incidence of new vertebral fractures in men receiving androgen deprivation therapy for prostate cancer. It also significantly improved bone mineral density, bone turnover markers and serum lipid profiles. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. [2010.07]
OBJECTIVE: Toremifene and tamoxifen have been used for adjuvant therapy in post-menopausal patients with breast cancer in Japan. Dyslipidemias are common in post-menopausal women. However, limited data are available on the effects of these agents on lipid profiles in Japanese patients. The Japan Toremifene Cooperative Study Group has been conducting a Phase III randomized trial of post-menopausal patients with breast cancer. One of its secondary endpoints is to confirm the effects of these agents on serum lipid profiles... CONCLUSIONS: Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of these improved lipid profiles on the risk of cardiovascular diseases needs further confirmation.

more studies >>

Clinical Trials Related to Fareston (Toremifene)

Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer [Recruiting]
To compare the safety of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer by monitoring gynecological abnormality,blood lipid level,hepatic abnormality,estrogen level and perimenopausal symptoms.

Changes in Breast 3D Ultrasound Measurements Using Toremifene [Completed]

The Effect of Toremifene Treatment to the Magnetic Resonance Imaging (MRI) Findings in Premenstrual Mastalgia [Completed]
The purpose of this study is to determine the effect of toremifene treatment to the MRI findings of the breast in women suffering from premenstrual mastalgia.

Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer [Recruiting]
This study evaluates the addition melatonin and metformin to toremifene in the treatment of locally advanced breast cancer. Third of patients will receive toremifene, other third will receive combination of melatonin and toremifene and other patients will receive combination of metformin and toremifene.

Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer [Terminated]
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the FDA-approved anti-estrogen toremifene (Fareston), to the single agent FDA-approved aromatase inhibitor letrozole (Femara) for the treatment of advanced breast cancer. The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of atamestane, plus toremifene (Fareston), is more effective than letrozole (Femara®) in delaying the growth of breast cancer.

more trials >>

Reports of Suspected Fareston (Toremifene) Side Effects

Hepatic Function Abnormal (4)White Blood Cell Count Decreased (4)Interstitial Lung Disease (3)Hepatitis Acute (2)Condition Aggravated (2)Bronchiectasis (2)Diarrhoea (2)Respiratory Failure (2)Neoplasm Progression (1)Osteomyelitis (1)more >>


Page last updated: 2015-08-28

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015